BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

PARTNERSHIPS

Business Development Opportunities

Working together to improve the lives of patients living with serious and debilitating chronic conditions.

BDSI actively seeks partnerships and product licenses in the areas of neurology, pain, psychiatry, and select rare diseases. We collaborate in ways that expand and strengthen the process of commercializing innovative therapies, and are open to working within a variety of mutually beneficial deal structures.

Working With BDSI

For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander.

Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050

Asterisks denote required fields

Recent BDSI News

September 11, 2020

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients

Read more
September 3, 2020

RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive

Read more
August 5, 2020

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 19, 2020BDSI $3.52/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.